There is a growing trend towards exploring the use of a minimally invasive “liquid biopsy” to
identify biomarkers in a number of cancers, including urologic malignancies. Multiple …

Abstract The CellSearch® system (CS) enables standardized enrichment and enumeration
of circulating tumor cells (CTCs) that are repeatedly assessable via non-invasive “liquid …

Context Invasive bladder cancer is a frequently occurring disease with a high mortality rate
despite optimal treatment. The European Association of Urology (EAU) Muscle-invasive and …

Bladder cancer is a major cause of morbidity, mortality and health-related costs. Urothelial
carcinoma is by far the most common histologic type of bladder cancer and may also arise …

BACKGROUND: Preliminary research has suggested the potential prognostic value of
circulating tumor cells (CTC) in patients with advanced nonmetastatic urothelial carcinoma …

Bladder cancer (BCa) is the most prevalent neoplasia of the urinary tract. Unfortunately,
limited improvements in effective BCa management have meant that it remains a …

Circulating tumor cells (CTCs) have emerged as pivotal biomarkers with significant
predictive and prognostic implications in solid tumors. Their presence in peripheral blood …

Bladder cancer is one of the most prevalent cancers worldwide, but the treatment and
management of this disease can be very successful if the disease is detected early. The …

Bladder Cancer (BC) represents a clinical and social challenge due to its high incidence
and recurrence rates, as well as the limited advances in effective disease management …

Background Advances in cancer genome sequencing have led to the development of
various next-generation sequencing (NGS) platforms. There is paucity of data regarding …